Malignancy photosensitizers

Definition

Malignancy photosensitizers are a specialized class of photodynamic therapy (PDT) agents used to treat various forms of cancer. These agents are administered systemically or topically and selectively accumulate in neoplastic tissues, where they can be activated by light of a specific wavelength, leading to the generation of reactive oxygen species (ROS) and targeted cytotoxicity.

The therapeutic principle of photodynamic therapy (PDT) combines:

• A photosensitizer drug (preferentially retained in tumor tissue),

• Light irradiation (usually from a laser source), and

• Oxygen (to produce ROS like singlet oxygen)

This results in cell apoptosis/necrosis, vascular shutdown, and immune activation, offering a non-invasive and highly localized treatment for select cancers.

---

Mechanism of Action

Malignancy photosensitizers function through the photodynamic reaction, which involves three elements:

1. Photosensitizer Administration

   • Accumulates in malignant cells due to altered permeability, receptor expression, or metabolic activity.

2. Light Activation (Typically Red Light 630–690 nm)

   • The photosensitizer is irradiated with light of an appropriate wavelength.

3. Excitation and ROS Generation

   • The photosensitizer transitions from ground to excited state, transferring energy to molecular oxygen to produce:

     • Singlet oxygen (¹O₂) – highly cytotoxic

     • Superoxide anions, hydroxyl radicals

These ROS lead to:

• Direct tumor cell death via oxidative damage to membranes, organelles, and DNA

• Destruction of tumor vasculature

• Induction of local and systemic immune responses

---

Generations of Photosensitizers

First-Generation

• Derived from hematoporphyrin derivatives

• Limitations: prolonged skin photosensitivity, slow clearance, weak selectivity

Examples:

• Photofrin® (porfimer sodium) — most established first-gen agent

Second-Generation

• Improved purity, tumor selectivity, and shorter photosensitivity duration

• Absorb light at longer wavelengths (deeper tissue penetration)

Examples:

• Temoporfin (Foscan®) – chlorin-based

• Verteporfin (Visudyne®) – benzoporphyrin derivative

Third-Generation (under development)

• Photosensitizers conjugated to antibodies, nanoparticles, or targeting moieties

• Enhanced tumor specificity and photochemical efficiency

Examples:

• Antibody–photosensitizer conjugates

• Nanoparticle-encapsulated chlorins or phthalocyanines

---

Representative Agents in Malignancy

Drug Name	Brand Name	Type	Indications
Porfimer sodium	Photofrin®	Hematoporphyrin derivative	Esophageal cancer, NSCLC, Barrett’s esophagus
Temoporfin	Foscan®	Chlorin derivative	Head and neck squamous cell carcinoma
Verteporfin	Visudyne®	Benzoporphyrin	Primarily AMD; investigated in pancreatic, gliomas
Redaporfin	—	Bacteriochlorin	Under trial for head & neck cancer, sarcoma
Pheophorbide A	—	Chlorin-like	Preclinical – glioblastoma, skin cancers
TLD1433	—	Ruthenium-based	Under trial for bladder cancer
Padeliporfin	Tookad®	Bacteriopheophorbide	Low-risk prostate cancer (EU approved)

Clinical Indications

PDT with malignancy photosensitizers is currently indicated or under investigation for:

FDA-Approved or EMA-Approved Uses

• Esophageal carcinoma (non-resectable) – Photofrin®

• Non-small cell lung cancer (NSCLC) – Photofrin®

• Barrett’s esophagus with high-grade dysplasia – Photofrin®

• Head and neck squamous cell carcinoma – Foscan® (EU only)

• Low-risk prostate cancer – Padeliporfin/Tookad® (EMA)

Investigational Uses

• Glioblastoma

• Bladder cancer (non-muscle invasive)

• Cholangiocarcinoma

• Pancreatic adenocarcinoma

• Basal cell and squamous cell carcinoma

• Sarcomas and peritoneal carcinomatosis

---

Administration Protocol

1. Photosensitizer Administration

   • Usually IV (e.g., Photofrin: 2 mg/kg IV)

   • Time is allowed for selective tumor accumulation (24–96 hours)

2. Light Irradiation

   • Laser light of specific wavelength (e.g., 630 nm for Photofrin)

   • Delivered through fiber-optic catheters, endoscopes, or surface applicators

3. Post-Treatment Precautions

   • Strict light protection protocols due to skin photosensitivity (up to 30 days)

   • Gradual reintroduction to sunlight

---

Pharmacokinetics

Agent	Absorption	Distribution	Half-life	Excretion
Porfimer sodium	IV only	Liver, tumor, skin	~400 hours (long)	Hepatobiliary/feces
Temoporfin	IV only	Lipophilic tissues, tumor	~240 hours	Feces (main), urine
Verteporfin	IV (5–10 min)	Highly protein-bound	~5 hours	Biliary route
Tookad (Padeliporfin)	IV	Selective in prostate vasculature	~1 hour	Fecal + biliary

Contraindications

• Porphyria or disorders of porphyrin metabolism

• Known hypersensitivity to the agent or excipients

• Pregnancy and lactation – safety not established

• Uncontrolled cardiovascular or hepatic disease (precautionary)

• Patients unable to comply with light protection protocols

---

Adverse Effects

System	Adverse Effect	Notes
Dermatologic	Phototoxic reactions (blistering, burning)	Avoid sunlight/bright light for days to weeks
Local (treatment site)	Edema, ulceration, necrosis	Related to targeted tissue necrosis
Respiratory	Cough, bronchospasm (if treating lung cancers)	Requires airway monitoring
GI	Nausea, vomiting, dysphagia	Especially in esophageal PDT
Cardiovascular	Hypotension, chest pain (rare)	Possible vasodilatory effect
Hematologic	Rare: anemia, leukopenia	Monitoring advised if large surface area treated

Drug Interactions

• Photosensitizers + sunlight or phototherapy → exaggerated phototoxicity

• Avoid concomitant use of:

  • Photosensitizing drugs (e.g., thiazides, sulfonamides, fluoroquinolones)

  • Strong CYP3A4 inducers/inhibitors (for agents metabolized hepatically)

• Immunosuppressants may reduce antitumor immune response elicited by PDT

---

Monitoring Parameters

• Baseline assessment of tumor size, site, oxygenation status

• Post-PDT imaging (CT/MRI) to assess tumor necrosis

• Phototoxicity: Monitor skin and eye exposure for 30 days

• Liver and renal function tests (especially with repeat dosing)

• Photosensitivity testing before sunlight re-exposure

---

Advantages of PDT in Oncology

• Highly localized cytotoxicity: minimal damage to surrounding tissues

• Repeatable: Does not induce resistance or cumulative toxicity like chemotherapy

• Minimal systemic toxicity

• Outpatient or minimally invasive procedure

• Dual action: Destroys both tumor cells and supporting vasculature

• Immune stimulation: Emerging evidence of abscopal effects (immune response against distant tumor)

---

Limitations

• Depth limitation: Light penetration is ~5–10 mm depending on wavelength

• Photosensitivity risk: Requires patient education and compliance

• Specialized equipment: Lasers, fibers, and trained personnel

• Not suitable for widely metastatic disease

• Variability in tumor uptake of photosensitizers

---

Emerging Research and Innovations

1. Third-Generation Targeted PDT Agents

   • Photosensitizers conjugated with monoclonal antibodies (e.g., anti-HER2)

   • Nanoparticles for enhanced permeability and retention (EPR effect)

2. Combination Therapy

   • PDT + immune checkpoint inhibitors (e.g., anti-PD-1)

   • PDT + chemotherapy/radiotherapy for synergistic effects

3. Photochemical Internalization (PCI)

   • Technique to enhance intracellular delivery of macromolecular drugs using PDT

4. Gene-Directed Enzyme Prodrug Therapy (GDEPT) + PDT

   • Use of light to activate gene therapy vectors or prodrugs at tumor site

5. Photoimmunotherapy (PIT)

   • Near-infrared (NIR) antibody-photosensitizer conjugates for ultra-specific targeting

---

Comparative Summary

Drug	Tissue Selectivity	Light Wavelength	Photosensitivity Duration	Approval Status
Photofrin	Moderate	630 nm	4–6 weeks	FDA, EMA
Foscan (Temoporfin)	High	652 nm	~2 weeks	EMA
Tookad	Prostate vasculature	763 nm	<24 hours	EMA (prostate cancer)
Verteporfin	Moderate	689 nm	2–5 days	FDA (ocular), trials for cancer

Regulatory Status

• Photofrin:

  • FDA-approved for esophageal cancer, NSCLC, and Barrett’s esophagus

  • EMA-approved for additional indications

• Foscan:

  • EMA-approved for palliative treatment of advanced head and neck cancer

• Tookad (Padeliporfin):

  • EMA-approved (Europe only) for low-risk prostate cancer

• Verteporfin:

  • FDA-approved for age-related macular degeneration; being repurposed in oncology trials